OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
June 07, 2023
Webinar Date/Time: Tuesday, June 27th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Wednesday, June 28th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT Thursday, June 29th, 2023 at 8am EDT | 1pm BST | 2pm CEST | 5am PDT
June 06, 2023
invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.
June 02, 2023
Nanotech-based delivery technologies are receiving significant attention.
Webinar Date/Time: Wed, Jul 19, 2023 1:00 PM EDT
June 01, 2023
A partnership between Rentschler Biopharma and Ikarovec will support the accelerated development of novel gene therapies for the treatment of eye diseases.
May 31, 2023
The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.
Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.
Webinar Date/Time: Wed, Jun 21, 2023 2:00 PM EDT
May 30, 2023
Webinar Date/Time: Thu, Jun 15, 2023 11:00 AM EDT
May 27, 2023
Sean Hart, CEO and SCO of LumaCyte, discusses rapid accurate mRNA potency assay possibilities.